Drug updated on 12/11/2024
| Dosage Form | Injection (intravenous; 1 mg per 2 mL [0.5 mg per mL]) |
| Drug Class | Microtubule inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease
- Prior therapy should have included an anthracycline and a taxane in either the
- adjuvant or metastatic setting
- Indicated for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.
Latest News
Summary
- This summary is based on the review of two systematic review(s)/meta-analysis(es). [1-2]
- Locally Advanced/Metastatic Breast Cancer: In a network meta-analysis, eribulin mesylate (ERI) demonstrated improved overall survival (OS) compared to treatment by physician's choice (TPC) (hazard ratio (HR): 0.81; credible interval (CrI): 0.66-0.99) and gemcitabine (GEM)+vinorelbine (VIN) (HR: 0.62; CrI: 0.42-0.90). ERI provided a longer progression-free survival (PFS) than TPC (HR: 0.76; CrI: 0.64-0.90) but was less effective than capecitabine (CAP)+ixabepilone (IXA) (HR: 1.40; CrI: 1.17-1.67) and CAP+utidelone (UTI) (HR: 1.61; CrI: 1.23-2.12).
- Triple Negative Breast Cancer (TNBC) Subgroup: In TNBC patients, ERI showed a statistically significant improvement in OS compared to CAP (HR: 0.70; CrI: 0.54-0.90), while there were no significant differences in PFS.
- Older Patients with Breast Cancer (≥70 years): In a pooled analysis, older patients treated with ERI had a median OS of 13.1 months, a median PFS of 4.8 months, and a pooled overall response rate (ORR) of 23.2%, with a disease control rate (DCR) of 47%.
- In older patients with breast cancer (pooled analysis), Grade 3-4 hematological toxicities included neutropenia (0-49%), with anemia and thrombocytopenia reported as rare; non-hematological toxicities included Grade 3-4 fatigue (5-16.5%) and neurotoxicity (0-10.1%). Dose reductions were necessary in 40% of patients (range 18.6-84%).
- There are no direct safety comparisons between eribulin mesylate (ERI) and other drugs (CAP, GEM, IXA, UTI, TPC, VIN) in the reviewed studies.
- There is no population types or subgroups information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Halaven (eribulin mesylate) Prescribing Information. | 2022 | Eisai Inc., Nutley, NJ |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer | 2021 | BMC Cancer |
| Efficacy of Eribulin mesylate in older patients with breast cancer: A pooled analysis of clinical trial and real-world data | 2020 | Journal of Geriatric Oncology |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Systemic anti-cancer therapy delivery in the home: a service model. | 2020 | British Journal of Nursing |